Skip to main content
editorial
. 2022 Feb 26;8:84. doi: 10.1038/s41420-022-00881-1

Fig. 6. A schematic representation of MYSM1-mediated RSK3 expression and cisplatin resistance.

Fig. 6

Upon cisplatin treatment on TNBC cells, MYSM1 represses RSK3 expression, and reduces the phosphorylation of BAD at Ser 112, leading to cell apoptosis and cisplatin sensitivity.